Drugs / 68Ga-DOTA-BPP
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06203119 | Mar 2024 → Dec 2025 | cancer | Peking University Cancer Hospital & Institute | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 68Ga-DOTA-BPP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06203119 ↗ |
| Modality | Diagnostic / imaging agent | “68Ga-DOTA-BPP is an ACE1-targeted PET radiotracer.” NCT06203119 ↗ |
| Route | Intravenous | “After intravenous administration of 3-5 mCi of quality-controlled 68Ga-DOTA-BPP” NCT06203119 ↗ |
| Target | ACE | “68Ga-DOTA-BPP is an ACE1-targeted PET radiotracer.” NCT06203119 ↗ |